Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$25.87 ▼ -1.36
(-4.99%)
MKT CAP: $2.67B • VOL: 1.45M
52W L $20 52W H $38
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$22
MEDIAN
$29
MEAN
$29
HIGH
$35
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BEAM TAPE
BEAM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $31.30 | $29.75 | 2025-02-14 | $23.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $32.60 | $30.53 | 2025-02-06 | $24.32 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $29.49 | $28.46 | 2025-01-29 | $24.84 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $26.39 | — | 2025-01-17 | $25.35 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $22.77 | $24.58 | 2025-01-09 | $23.02 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $30.79 | $26.90 | 2024-12-18 | $22.51 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $25.09 | $26.13 | 2024-12-04 | $24.06 | -4.3% | 48% | C |